Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial

Michail Ignatiadis*, Andrew Bailey, Heather Mcarthur, Sarra El-Abed, Evandro De azambuja, Otto Metzger, Stephen y. Chui, Max Dieterich, Thomas Perretti, Esther Shearer-Kang, Luciana Molinero, Günther g. Steger, Jacek Jassem, Soo chin Lee, Michaela Higgins, Jose Zarba, Marcus Schmidt, Henry Gomez, Angel Guerrero zotano, Luca MoscettiJoanne Chiu, Elisabetta Munzone, Noa efrat Ben-Baruch, Emilio Bajetta, Shinji Ohno, Seock-Ah Im, Gustavo Werutsky, Einav nili Gal-Yam, Xavier Gonzalez farre, Ling-Ming Tseng, William Jacot, Oleg Gluz, Zhimin Shao, Yaroslav Shparyk, Anastasia Zimina, Eric Winer, David a. Cameron, Giuseppe Viale, Shigehira Saji, Richard Gelber, Martine Piccart

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology